dateReleased: |
11-14-2014
|
description: |
High levels of hepcidin, the main regulator of systemic iron metabolism leads to various diseases. Targeting hepcidin and lowering its concentration is a possible form of intervention in order to treat these diseases. High turnover rate of hepcidin is a major drawback of therapies directly targeting this peptide. We developed two monoclonal antibodies (mAbs) ABT-207 and h5F9-AM8 which inhibit hemojuvelin also known as repulsive guidance molecule c (RGMc) and downregulate hepcidin. After a single application of these antibodies hepcidin expression in liver and its concentration in serum were reduced. Serum iron increased for several weeks. The RGMc antibodies show a pronounced dose response relationship in rats with h5F9-AM8 having an IC50 (UIBC) of ~80 fold higher than ABT-207. When hepcidin levels were downregulated iron deposition in the liver was visible histologically one week post application. The anitbody-mediated iron deposition was not associated with any toxicologically relevant effect at the doses and timepoints evaluate. Iron depositions seen after 14 weekly treatments with ABT-207 were partially reversible in rats and in cynomolgus monkeys. Due to their long-lasting effects and excellent safety profile, both RGMc-blocking antibodies ABT-207 and h5F9-AM8 are favorable clinical candidates for diseases characterized by high serum hepcidin levels like anemia of chronic disease. Female Sprague-Dawley rats [Crl:CD®(SD)IGS BR], weighing ~200 g at study initiation were obtained from Charles River Laboratories, Inc. Rats were housed singly in ventilated, stainless steel, wire-bottom hanging cages, fed non-certified Rodent Chow and water ad libitum and acclimated for at least 5 days after arrival. Rats were randomly assigned to various treatment groups (5 rats/group) and were dosed once weekly by IV injection via tail vein with vehicle (30mM Histidine, 8% w/v Sucrose, pH6.0, + 0.02% Tween 80) or with 0.02, 0.2, or 20 mg/kg of RGMc antibody for a total of 4 doses. All rats were sacrificed under isoflurane anesthesia 24 hours after final dose. Liver and spleen waere flash frozen in liquid nitrogen and stored at 80°C until processing for gene expression profiling on the Affymetrix platform. total of 12 samples, 3 biological replicates (rats) from each of 4 treatments groups 1. vehicle control (30mM Histidine, 8% w/v Sucrose, pH6.0, + 0.02% Tween 80) 2. 0.02 mg/kg RGMC Ab 3. 0.2 mg/kg RGMC Ab 4. 20 mg/kg RGMC Ab; rats were dosed by IV injection via tail vein once weekly for 4 total doses, dose volume 2mL/kg/week
|
privacy: |
not applicable
|
aggregation: |
instance of dataset
|
ID: |
E-GEOD-63200
|
refinement: |
raw
|
alternateIdentifiers: |
63200
|
keywords: |
functional genomics
|
dateModified: |
11-28-2014
|
availability: |
available
|
types: |
gene expression
|
name: |
Rattus norvegicus
|
ID: |
A-AFFY-43
|
name: |
Affymetrix GeneChip Rat Genome 230 2.0 [Rat230_2]
|
accessURL: | https://www.ebi.ac.uk/arrayexpress/files/E-GEOD-63200/E-GEOD-63200.raw.1.zip |
storedIn: |
ArrayExpress
|
qualifier: |
gzip compressed
|
format: |
TXT
|
accessType: |
download
|
authentication: |
none
|
authorization: |
none
|
accessURL: | https://www.ebi.ac.uk/arrayexpress/files/E-GEOD-63200/E-GEOD-63200.processed.1.zip |
storedIn: |
ArrayExpress
|
qualifier: |
gzip compressed
|
format: |
TXT
|
accessType: |
download
|
authentication: |
none
|
authorization: |
none
|
accessURL: | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63200 |
storedIn: |
Gene Expression Omnibus
|
qualifier: |
not compressed
|
format: |
HTML
|
accessType: |
landing page
|
primary: |
true
|
authentication: |
none
|
authorization: |
none
|
abbreviation: |
EBI
|
homePage: | http://www.ebi.ac.uk/ |
ID: |
SCR:004727
|
name: |
European Bioinformatics Institute
|
homePage: | https://www.ebi.ac.uk/arrayexpress/ |
ID: |
SCR:002964
|
name: |
ArrayExpress
|